The translocation results in the inappropriate activation of the BCL2 gene, which is placed under the control of the IgH promoter on chromosome 14. This leads to an overproduction of the BCL2 protein, which inhibits apoptosis, or programmed cell death. The resistance to apoptosis allows cells to survive longer than they should, contributing to the development and progression of cancer.
